Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Coakley

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Pharmacotherapy|September 2, 2004
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadonePatrick F Smith, Brian P Kearney, Sandra Liaw, et al.
Clinical Pharmacology and Therapeutics|November 1, 1996
Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysisC A Knupp, L J Hak, D F Coakley, et al.
Annals of Internal Medicine|September 11, 2003
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trialKathleen Squires, Anton L Pozniak, Gerald Pierone, et al.
Molecular Genetics and Metabolism Reports|June 27, 2017
Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrateM Mokhtarani, G A Diaz, U Lichter-Konecki, et al.
Molecular Genetics and Metabolism|March 18, 2014
Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomesSusan A Berry, Uta Lichter-Konecki, George A Diaz, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials GroupW T Hughes, J L Shenep, J H Rodman, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsP Barditch-Crovo, S G Deeks, A Collier, et al.
British Journal of Cancer|April 14, 2015
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trialA P Algazi, E Cha, S M Ortiz-Urda, et al.
The Journal of Pediatrics|January 18, 2013
Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrateWendy Smith, George A Diaz, Uta Lichter-Konecki, et al.
Digestive Diseases and Sciences|January 20, 2016
Prospective Multicenter Observational Study of Overt Hepatic EncephalopathyC S Landis, M Ghabril, V Rustgi, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Pharmacotherapy|September 2, 2004
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadonePatrick F Smith, Brian P Kearney, Sandra Liaw, et al.
Clinical Pharmacology and Therapeutics|November 1, 1996
Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysisC A Knupp, L J Hak, D F Coakley, et al.
Annals of Internal Medicine|September 11, 2003
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trialKathleen Squires, Anton L Pozniak, Gerald Pierone, et al.
Molecular Genetics and Metabolism Reports|June 27, 2017
Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrateM Mokhtarani, G A Diaz, U Lichter-Konecki, et al.
Molecular Genetics and Metabolism|March 18, 2014
Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomesSusan A Berry, Uta Lichter-Konecki, George A Diaz, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials GroupW T Hughes, J L Shenep, J H Rodman, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsP Barditch-Crovo, S G Deeks, A Collier, et al.
British Journal of Cancer|April 14, 2015
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trialA P Algazi, E Cha, S M Ortiz-Urda, et al.
The Journal of Pediatrics|January 18, 2013
Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrateWendy Smith, George A Diaz, Uta Lichter-Konecki, et al.
Digestive Diseases and Sciences|January 20, 2016
Prospective Multicenter Observational Study of Overt Hepatic EncephalopathyC S Landis, M Ghabril, V Rustgi, et al.
Pageof 5